Juvenile dermatomyositis

Summary

Juvenile dermatomyositis (MONDO:0008054) is a disease with 5 cohort genes (22 GWAS associations across 4 studies) and 26 clinical trials. Top therapeutic interventions include baricitinib, corticotropin, and cyclophosphamide anhydrous.

At a glance

• Prevalence: 1-9 / 1 000 000 (Worldwide) [Orphanet-validated]
• Cohort genes: 5
• GWAS associations: 22
• Phenotypes (HPO): 45
• Clinical trials: 26

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	1-9 / 1 000 000	0.295	Worldwide	Validated

Signs & symptoms

Clinical features (HPO)

45 HPO clinical features (Orphanet curated; top 45 by frequency):

HPO ID	Term	Frequency
HP:0000958	Dry skin	Very frequent (80-99%)
HP:0000988	Skin rash	Very frequent (80-99%)
HP:0001324	Muscle weakness	Very frequent (80-99%)
HP:0002960	Autoimmunity	Very frequent (80-99%)
HP:0003236	Elevated circulating creatine kinase concentration	Very frequent (80-99%)
HP:0003326	Myalgia	Very frequent (80-99%)
HP:0003565	Elevated erythrocyte sedimentation rate	Very frequent (80-99%)
HP:0003761	Calcinosis	Very frequent (80-99%)
HP:0010783	Erythema	Very frequent (80-99%)
HP:0011227	Elevated circulating C-reactive protein concentration	Very frequent (80-99%)
HP:0012378	Fatigue	Very frequent (80-99%)
HP:0100540	Palpebral edema	Very frequent (80-99%)
HP:0100579	Mucosal telangiectasiae	Very frequent (80-99%)
HP:0100585	Telangiectasia of the skin	Very frequent (80-99%)
HP:0100614	Myositis	Very frequent (80-99%)
HP:0000989	Pruritus	Frequent (30-79%)
HP:0000992	Cutaneous photosensitivity	Frequent (30-79%)
HP:0001029	Poikiloderma	Frequent (30-79%)
HP:0001252	Hypotonia	Frequent (30-79%)
HP:0001369	Arthritis	Frequent (30-79%)
HP:0001596	Alopecia	Frequent (30-79%)
HP:0001945	Fever	Frequent (30-79%)
HP:0002019	Constipation	Frequent (30-79%)
HP:0002091	Restrictive ventilatory defect	Frequent (30-79%)
HP:0002633	Vasculitis	Frequent (30-79%)
HP:0002829	Arthralgia	Frequent (30-79%)
HP:0003394	Muscle spasm	Frequent (30-79%)
HP:0200042	Skin ulcer	Frequent (30-79%)
HP:0001260	Dysarthria	Occasional (5-29%)
HP:0001376	Limitation of joint mobility	Occasional (5-29%)
HP:0001609	Hoarse voice	Occasional (5-29%)
HP:0001618	Dysphonia	Occasional (5-29%)
HP:0001638	Cardiomyopathy	Occasional (5-29%)
HP:0001681	Angina pectoris	Occasional (5-29%)
HP:0001701	Pericarditis	Occasional (5-29%)
HP:0001824	Weight loss	Occasional (5-29%)
HP:0002015	Dysphagia	Occasional (5-29%)
HP:0002027	Abdominal pain	Occasional (5-29%)
HP:0002094	Dyspnea	Occasional (5-29%)
HP:0002206	Pulmonary fibrosis	Occasional (5-29%)
HP:0002239	Gastrointestinal hemorrhage	Occasional (5-29%)
HP:0003457	EMG abnormality	Occasional (5-29%)
HP:0011675	Arrhythmia	Occasional (5-29%)
HP:0011710	Bundle branch block	Occasional (5-29%)
HP:0012735	Cough	Occasional (5-29%)

Identifiers

Disease identifiers

Field	Value
Canonical name	juvenile dermatomyositis
Mondo ID	MONDO:0008054
EFO	EFO:0000557
MeSH	C000598745
Orphanet	93672
DOID	DOID:14203
ICD-10-CM	M33.0
ICD-11	1428089375
NCIT	C27576
SNOMED CT	1212005
UMLS	C0263666
MedGen	120486
GARD	0006805
MedDRA	10008521
Is cancer (heuristic)	no

Also known as: childhood dermatomyositis · inflammation of myoseptum · JDM · JPM · juvenile dermatomyositis · juvenile DM · juvenile myositis · myoseptum inflammation · myoseptumitis

Data availability: 22 GWAS associations (4 studies) · 1 cell line.

Disease family

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › dermatomyositis › juvenile dermatomyositis

Related subtypes (10): adult dermatomyositis, neonatal dermatomyositis, classical dermatomyositis, adermatopathic dermatomyositis, anti-MDA5 dermatomyositis, anti-Mi2 dermatomyositis, anti-NXP2 dermatomyositis, anti-TIF1 dermatomyositis, anti-SAE dermatomyositis, clinically amyopathic dermatomyositis

Genetics & variants

GWAS landscape

22 GWAS associations across 4 studies. Top hits map to 16 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs3129843	2e-48	TSBP1-AS1 - HLA-DRA	G	2.18
rs3117103	2e-20	TSBP1-AS1	?	1.87
rs12204922	8e-16	HLA-DRB9 - HLA-DRB5	?	1.91
HLA-DRB1*03:01	1e-14		?	1.66
rs139672953	3e-09	RNU6-695P - LINC02787	?	5.1
rs140108689	8e-09	MRPS9-AS2	?	4.23
rs73958160	1e-08	GPAT2 - ADRA2B	?	3.39
rs116386365	2e-08	IL17A - IL17F	?	6.28
rs78829749	2e-08	LY86-AS1, LY86	?	4.48
rs6501160	6e-08	TMEM114	?	0.72
HLA-C*02:02	7e-08		?	1.74
rs112016802	7e-08	SYBU	?	3.58
HLA-DQB1*02:01	9e-08		?	1.62
rs192074881	2e-07	FANCC	?	3.26
rs11568763	3e-07	TGFBR1	?	3.19
rs182199585	6e-07	SULT2B1	?	2.59
rs6892006	9e-07	MEF2C-AS1	?	0.68
rs7255994	9e-07	EMP3	?	1.94
rs4702698	5e-06	LINC02213, ROPN1L	G	1.22
rs4921293	8e-06	MIR3142HG	G	1.21
rs1008723	9e-06	GSDMB	T	1.2
rs113703584	9e-06	ARID3A	?	0.67

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST006053	Rothwell S	2015	879	15,651	Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups.
GCST90162630	Deakin CT	2022	851	12,232	Association with HLA-DRβ1 position 37 distinguishes juvenile Dermatomyositis from adult-onset myositis.
GCST90162637	Deakin CT	2022	851	12,232	Association with HLA-DRβ1 position 37 distinguishes juvenile Dermatomyositis from adult-onset myositis.
GCST90270219	Rothwell S	2022	508	10,260	Genome-wide imputation identifies novel associations and localises signals in idiopathic inflammatory myopathies.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	22

MAF distribution

Bucket	Variants
common (>=0.05)	10
low_freq (0.01-0.05)	10
rare (<0.01)	0
unknown	2

Functional consequences

Consequence	Count
intron_variant	14
intergenic_variant	4
unknown	3
non_coding_transcript_exon_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs3129843	6	32427949	A>G	0.05	intron_variant	TSBP1-AS1 - HLA-DRA	2e-48	Tier 4: intronic/intergenic
rs3117103	6	32381780	A>T	0.05	intron_variant	TSBP1-AS1	2e-20	Tier 4: intronic/intergenic
rs12204922	6	32483836	A>C,T	0.05	intron_variant	HLA-DRB9 - HLA-DRB5	8e-16	Tier 4: intronic/intergenic
HLA-DRB1*03:01				0.12			1e-14	Tier 4: intronic/intergenic
rs139672953	1	90314120	T>G	0.01	intergenic_variant	RNU6-695P - LINC02787	3e-09	Tier 4: intronic/intergenic
rs140108689	2	104979261	T>C	0.01	intron_variant	MRPS9-AS2	8e-09	Tier 4: intronic/intergenic
rs73958160	2	96082421	G>A,C,T	0.02	intergenic_variant	GPAT2 - ADRA2B	1e-08	Tier 4: intronic/intergenic
rs116386365	6	52204037	C>A,G,T	0.01	intron_variant	IL17A - IL17F	2e-08	Tier 4: intronic/intergenic
rs78829749	6	6594252	C>T	0.01	intron_variant	LY86-AS1, LY86	2e-08	Tier 4: intronic/intergenic
rs6501160	16	8557137	G>A,C	0.27	intergenic_variant	TMEM114	6e-08	Tier 4: intronic/intergenic
HLA-C*02:02							7e-08	Tier 4: intronic/intergenic
rs112016802	8	109641896	C>T	0.01	intron_variant	SYBU	7e-08	Tier 4: intronic/intergenic
HLA-DQB1*02:01							9e-08	Tier 4: intronic/intergenic
rs192074881	9	95292358	G>A,T	0.02	non_coding_transcript_exon_variant	FANCC	2e-07	Tier 4: intronic/intergenic
rs11568763	9	99130791	G>A	0.02	intron_variant	TGFBR1	3e-07	Tier 4: intronic/intergenic
rs182199585	19	48560940	C>G	0.03	intron_variant	SULT2B1	6e-07	Tier 4: intronic/intergenic
rs6892006	5	89154724	T>G	0.13	intron_variant	MEF2C-AS1	9e-07	Tier 4: intronic/intergenic
rs7255994	19	48323853	T>C	0.04	intergenic_variant	EMP3	9e-07	Tier 4: intronic/intergenic
rs4702698	5	10517796	A>G	0.05	intron_variant	LINC02213, ROPN1L	5e-06	Tier 4: intronic/intergenic
rs4921293	5	160501869	A>G,T	0.05	intron_variant	MIR3142HG	8e-06	Tier 4: intronic/intergenic
rs1008723	17	39910014	G>C,T	0.05	intron_variant	GSDMB	9e-06	Tier 4: intronic/intergenic
rs113703584	19	936297	G>A,C	0.05	intron_variant	ARID3A	9e-06	Tier 4: intronic/intergenic

Genes & proteins

Mendelian disease overlap and somatic drivers

GenCC: 0 · Orphanet: 0 · OMIM-shared: 0 · Dual-evidence (GWAS+Mendelian): 0

Cohort genes → proteins

5 cohort genes, 5 distinct canonical proteins.

Evidence partition

Subset	Genes
gwas_only	5

Cohort genes (full)

Symbol	HGNC	Ensembl	UniProt	Name	Evidence
ATP10B	HGNC:13543	ENSG00000118322	O94823	Phospholipid-transporting ATPase VB	gwas
GSDMB	HGNC:23690	ENSG00000073605	Q8TAX9	Gasdermin-B	gwas
ROPN1L	HGNC:24060	ENSG00000145491	Q96C74	Ropporin-1-like protein	gwas
ANKRD33B	HGNC:35240	ENSG00000164236	A6NCL7	Ankyrin repeat domain-containing protein 33B	gwas
PTTG1	HGNC:9690	ENSG00000164611	O95997	Securin	gwas

Cohort function summary

Lead sentence per gene, UniProt-curated.

Symbol	Protein name	Function (lead sentence)
ATP10B	Phospholipid-transporting ATPase VB	Catalytic component of a P4-ATPase flippase complex, which catalyzes the hydrolysis of ATP coupled to the transport of glucosylceramide (GlcCer) from the outer to the inner leaflet of lysosome membranes.
GSDMB	Gasdermin-B	Precursor of a pore-forming protein that acts as a downstream mediator of granzyme-mediated cell death.
ROPN1L	Ropporin-1-like protein	Functions as part of axonemal radial spoke complexes that play an important part in the motility of sperm and cilia.
PTTG1	Securin	Regulatory protein, which plays a central role in chromosome stability, in the p53/TP53 pathway, and DNA repair.

Protein-family classification

Druggable: 0 · Difficult: 2 · Unknown: 3 · Druggable fraction: 0.0

Family distribution

Cohort families vs a genome-wide background (hypergeometric, BH-FDR; fold = observed/expected). Counts kept; sorted by enrichment, so the catch-all Other/Unknown bucket no longer leads.

Family	Genes	Fold	FDR
Scaffold/PPI	1	3.5×	0.608
Transcription factor	1	1.6×	0.608
Other/Unknown	3	1.1×	0.608

Per-gene assignment

Symbol	Family	Druggable?	EC	InterPro (top 3)
ATP10B	Transcription factor	no	7.6.2.1	P_typ_ATPase, P-type_ATPase_IV, ATPase_P-typ_transduc_dom_A_sf
GSDMB	Other/Unknown	no		Gasdermin, Gasdermin_pore, Gasdermin_PUB
ROPN1L	Other/Unknown	no		ROP_DD
ANKRD33B	Scaffold/PPI	no		Ankyrin_rpt, Ankyrin_rpt-contain_sf
PTTG1	Other/Unknown	no		Securin_separation_inhibitor

Expression context

Cohort genes with no expression data: 0.

5 cohort genes are a single-cell marker in ≥1 SCXA experiment.

Breadth distribution (Bgee present_calls)

Bucket	Genes
narrow (1-5 tissues)	0
moderate (6-20)	0
broad (>20)	5
unknown	0

Top tissues across cohort

Tissue	Cohort genes
colonic mucosa	1
mucosa of sigmoid colon	1
palpebral conjunctiva	1
mucosa of transverse colon	1
rectum	1
right lobe of liver	1
bronchial epithelial cell	1
left testis	1
right testis	1
Brodmann (1909) area 23	1
sural nerve	1
tibialis anterior	1
oocyte	1
secondary oocyte	1
ventricular zone	1

Per-gene tissue summary (top 30)

Symbol	Bgee breadth	FANTOM5 breadth	SCXA	Top tissues
ATP10B	220	tissue_specific	marker	mucosa of sigmoid colon, colonic mucosa, palpebral conjunctiva
GSDMB	206	tissue_specific	marker	rectum, right lobe of liver, mucosa of transverse colon
ROPN1L	167	broad	marker	left testis, right testis, bronchial epithelial cell
ANKRD33B	178	ubiquitous	marker	tibialis anterior, Brodmann (1909) area 23, sural nerve
PTTG1	246	ubiquitous	marker	oocyte, secondary oocyte, ventricular zone

Protein interactions among cohort

Intra-cohort edges: 0.

Hub genes (top 10 by interactor count)

Symbol	Interactor count
PTTG1	2,225
ANKRD33B	1,486
ATP10B	970
ROPN1L	945
GSDMB	703

Structural data

PDB: 3 · AlphaFold-only: 2 · No structure: 0

Cohort genes with PDB structures (top 30)

Symbol	UniProt	PDB entries
GSDMB	Q8TAX9	11
PTTG1	O95997	2
ROPN1L	Q96C74	1

AlphaFold-only cohort genes (top 30 by pLDDT)

Symbol	UniProt	pLDDT
ATP10B	O94823	71.60
ANKRD33B	A6NCL7	67.74

Function

Pathway analysis

Distinct Reactome pathways touched by cohort: 6. Enrichment computed across 5 evidence-associated genes (2 with Reactome annotation).

Pathways by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 2 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

Pathway	Cohort genes	Fold	FDR	Sample cohort genes
Ion transport by P-type ATPases	1	103.8×	0.023	ATP10B
APC/C:Cdc20 mediated degradation of Securin	1	95.2×	0.023	PTTG1
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1	1	85.2×	0.023	PTTG1
Ion channel transport	1	48.0×	0.031	ATP10B
Separation of Sister Chromatids	1	30.4×	0.039	PTTG1
Transport of small molecules	1	12.6×	0.078	ATP10B

GO biological processes by enrichment

Over-representation of cohort genes vs the genome-wide background (hypergeometric test, Benjamini-Hochberg FDR; fold = observed/expected over 4 annotated cohort genes). Counts and members are kept as ground-truth; sorted by enrichment.

GO term	Cohort genes	Fold	FDR	Sample cohort genes
lysosomal membrane organization	1	4213.0×	0.004	ATP10B
cytotoxic T cell pyroptotic cell death	1	2106.5×	0.004	GSDMB
homologous chromosome segregation	1	842.6×	0.007	PTTG1
obsolete killing by host of symbiont cells	1	351.1×	0.010	GSDMB
programmed cell death	1	324.1×	0.010	GSDMB
epithelial cilium movement involved in extracellular fluid movement	1	191.5×	0.013	ROPN1L
sperm capacitation	1	168.5×	0.013	ROPN1L
phospholipid translocation	1	156.0×	0.013	ATP10B
chromosome organization	1	145.3×	0.013	PTTG1
pyroptotic inflammatory response	1	127.7×	0.013	GSDMB
killing of cells of another organism	1	68.0×	0.023	GSDMB
defense response to Gram-negative bacterium	1	42.1×	0.033	GSDMB
flagellated sperm motility	1	29.3×	0.044	ROPN1L
defense response to bacterium	1	27.0×	0.044	GSDMB
DNA repair	1	16.0×	0.069	PTTG1
cell division	1	11.5×	0.089	PTTG1
spermatogenesis	1	8.8×	0.109	PTTG1

Therapeutics

Drugs indicated for this disease

1 approved, 4 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Prednisone	Approved (phase 4)
Baricitinib	Phase 3 (in late-stage trials)
Cyclosporine	Phase 3 (in late-stage trials)
Methotrexate	Phase 3 (in late-stage trials)
Methylprednisolone	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Rituximab.

Drug target analysis

Approved (phase 4): 0 · Phase ≥3: 0 · Phased (≥1): 0 · Undrugged: 5

Druggability breadth: 0 of 5 evidence-associated genes (0%) have a ChEMBL target (buckets above are over the deeply-mined display cohort).

Top cohort targets by molecule count

Symbol	Molecules	Max phase
ATP10B	0	0
GSDMB	0	0
ROPN1L	0	0
ANKRD33B	0	0
PTTG1	0	0

Bioactivity and enzyme data

Enzyme cohort genes (≥1 EC): 1.

Cohort enzymes (BRENDA EC)

Symbol	EC numbers	Names
ATP10B	7.6.2.1	P-type phospholipid transporter

Pharmacogenomics

Cohort genes with a PharmGKB record: 5; with CPIC/DPWG dosing guidelines: 0.

No cohort gene has a CPIC/DPWG genotype-guided dosing guideline (PharmGKB).

Chemical tractability of cohort targets

0 approved/phased compounds have measured bioactivity against a cohort gene (and aren’t yet in disease-level trials). This is a research / tractability signal, NOT a therapeutic recommendation — a bioactivity row often reflects off-target or screening binding (e.g. promiscuous kinase inhibitors against a cohort kinase), implying no disease mechanism.

Druggability pyramid

Cohort genes binned by druggability tier (high → low):

Tier	Definition	Genes	Symbols
A	Approved (phase 4 drug)	0
B	Phased (≥1) drug, not yet approved	0
C	Druggable family + PDB, no drug	0
D	Druggable family + AlphaFold only, no drug	0
E	Difficult family or no structure, no drug	5	ATP10B, GSDMB, ROPN1L, ANKRD33B, PTTG1

Undrugged target profiles

5 cohort genes are undrugged. Ranked by ‘starting-point quality’ (assay depth + drugged-partner adjacency).

Symbol	ChEMBL assays	Drugged partners (top 3)
ATP10B	0	—
GSDMB	0	—
ROPN1L	0	—
ANKRD33B	0	—
PTTG1	0	—

Clinical trials & evidence

Clinical trials

Clinical trials: 26.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	14
PHASE2	4
PHASE4	3
PHASE1	2
PHASE3	1
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00815282	PHASE4	COMPLETED	Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease
NCT01151644	PHASE4	UNKNOWN	Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases
NCT02245841	PHASE4	COMPLETED	Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis
NCT06154252	PHASE2/PHASE3	RECRUITING	RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
NCT00323960	PHASE3	COMPLETED	Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis
NCT07089121	PHASE1/PHASE2	RECRUITING	Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
NCT07111065	PHASE2	RECRUITING	FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
NCT00106184	PHASE2	COMPLETED	Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)
NCT05000216	PHASE2	TERMINATED	COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders
NCT05524311	PHASE2	COMPLETED	Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)
NCT06569472	PHASE1	RECRUITING	Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
NCT07184450	PHASE1	RECRUITING	Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases
NCT00059748	Not specified	RECRUITING	Studies of the Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases Including Juvenile Dermatomyositis
NCT01276470	Not specified	RECRUITING	Environmental Risk Factors for the Anti-synthetase Syndrome
NCT07374107	Not specified	RECRUITING	MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)
NCT01217320	Not specified	UNKNOWN	Creatine Supplementation in Pediatric Rheumatology
NCT01697254	Not specified	COMPLETED	The CARRA Registry
NCT01724580	Not specified	APPROVED_FOR_MARKETING	Compassionate Use Protocol for the Treatment of Autoinflammatory Syndromes
NCT02267005	Not specified	COMPLETED	The Effect of Creatine Supplementation on Muscle Function in Childhood Myositis
NCT03430388	Not specified	COMPLETED	Yellow Fever Vaccine in Patients With Rheumatic Diseases
NCT03432455	Not specified	UNKNOWN	Incidence and Prevalence of Juvenile Dermatomyositis
NCT03433638	Not specified	UNKNOWN	Juvenile Dermatomyositis
NCT05509140	Not specified	COMPLETED	Clinical Analysis of Juvenile Dermatomyositis Patients
NCT05545839	Not specified	COMPLETED	Transition to Adulthood Through Coaching and Empowerment in Rheumatology
NCT06556992	Not specified	COMPLETED	Fitness Integrative Training for Pediatric Rheumatology Disorders
NCT07138157	Not specified	COMPLETED	Comparison Of The Effects Of Two Different Exercise Training Based On Internal And External Focus In Children and Adolescents With Rheumatic Diseases

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BARICITINIB	4	1
CORTICOTROPIN	4	1
CYCLOPHOSPHAMIDE ANHYDROUS	4	1
ELASOMERAN	4	1
TOZINAMERAN	4	1
CREATINE	3	1
YELLOW FEVER VACCINE	3	1
CHEMBL5427854	0	1